---
title: "Non-invasive Imaging to Guide Percutaneous Coronary Revascularization in Chronic Total Occlusion: a Systematic Review and Meta-Analysis"
subtitle: "ESC 2024, London"
description: "A companion to the on-site study presentation"
categories: [cmr, chronic total occlusion, meta-analysis, systematic review]
author: 
    - name: G. Bisaccia
      orcid: 0000-0003-4606-3093
      affiliation: Royal Brompton and Harefield Hospitals, London, UK
date: 07/30/2024
date-format: "MMMM YYYY"
#image: 
draft: false # change status
reference-location: margin
execute:
    echo: false
    warning: false
    error: false
lightbox: true
title-block-categories: true
bibliography: cto.bib
---
Please refer to the study poster for the full list of authors contributing to this work.

# PRISMA Flow diagram

![](images/PRISMA.png)

# Characteristics of included studies

Included studies are described in @tbl-1.

+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| **Authors**                                                              | **Year**  | **Design** | **Sample size** | **Follow-up (months)** | **Modality** |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Werner et al. (EuroCTO) @RN42 @RN3                                       | 2023      | RCT        | 396             | 37                     | Mixed        |
|                                                                          |           |            |                 |                        |              |
|                                                                          | 2018      |            |                 |                        |              |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| De Winter et al. @RN11                                                   | 2022      | NROS       | 164             | 3                      | PET          |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Zhang et al. @RN27                                                       | 2022      | NROS       | 55              | 12                     | CMR          |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Song et al. @RN30                                                        | 2021      | NROS       | 2659            | 60                     | PET          |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Shokry et al. @RN20                                                      | 2021      | NROS       | 48              | 6                      | CMR          |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Schumacher et al. @RN25                                                  | 2021      | NROS       | 212             | 34                     | PET          |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Schumacher et al. @RN9                                                   | 2021      | NROS       | 132             | 3                      | CMR          |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Everaars et al. @RN21                                                    | 2021      | NROS       | 150             | 3                      | CMR          |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Vitadello et al. @RN28                                                   | 2020      | NROS       | 49              | 4                      | Mixed        |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Umeji et al. @RN24                                                       | 2020      | NROS       | 42              | 18                     | SPECT        |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Lee et al. @RN2 (DECISION-CTO)                                           | 2019      | RCT        | 834             | 48                     | Mixed        |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Schumacher et al. @RN26                                                  | 2019      | NROS       | 92              | NR                     | PET          |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Obedinskiy et al. @RN41\                                                 | 2018      | RCT        | 94              | 12                     | CMR          |
| (IMPACTOR-CTO)                                                           |           |            |                 |                        |              |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Mashayekhi et al. @RN32 (REVASC)                                         | 2018      | RCT        | 205             | 12                     | CMR          |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Galassi et al. @RN23                                                     | 2017      | NROS       | 839             | 16                     | Mixed        |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Stuijfzand et al. @RN8                                                   | 2017      | NROS       | 69              | 3                      | PET          |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Henriques et al. @RN4, Elias et al. @RN22, Elias et al. @RN33 (EXPLORE)\ | 2016-2018 | RCT        | 180             | 4                      | CMR          |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Bucciarelli-Ducci et al. @RN10                                           | 2016      | NROS       | 32              | 3                      | CMR          |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Rossello et al. @RN34                                                    | 2016      | NROS       | 47              | 6                      | CMR          |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Cardona et al. @RN31                                                     | 2016      | NROS       | 32              | 6                      | CMR          |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Chadid et al. @RN37                                                      | 2015      | NROS       | 43              | 9                      | CMR          |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Roifman et al. @RN38                                                     | 2013      | NROS       | 30              | 5                      | CMR          |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Pujadas et al. @RN36                                                     | 2013      | NROS       | 33              | 6                      | CMR          |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Borgia et al. @RN43                                                      | 2012      | NROS       | 302             | 48                     | CMR          |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Sun et al. @RN39                                                         | 2012      | NROS       | 99              | 12                     | SPECT        |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Kirschbaum et al. @RN35                                                  | 2012      | NROS       | 43              | 6                      | CMR          |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Safley et al. @RN29                                                      | 2011      | NROS       | 301             | 12                     | Mixed        |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Kirschbaum et al. @RN19                                                  | 2008      | NROS       | 21              | 32                     | CMR          |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Cheng et al. @RN44                                                       | 2008      | NROS       | 17              | 6                      | CMR          |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Heyne et al. @RN40                                                       | 2007      | NROS       | 13              | 5                      | CMR          |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+
| Baks et al. @RN18                                                        | 2006      | NROS       | 27              | 5                      | CMR          |
+--------------------------------------------------------------------------+-----------+------------+-----------------+------------------------+--------------+

: Baseline characteristics in included studies. {#tbl-1}

*MVD, multivessel disease; NR, data not reported; NROS, nonrandomized observational study; RCT, randomized clinical trial. For RCTs on CTO-PCI, J-CTO score refers to the PCI cohort. * for these referenced publications reporting on the same cohort, different outcomes were extracted from each.*

# Primary endpoint

![The forest plot shows the incidence rates along with the pooled estimate for the primary composite endpoint of all-cause death and nonfatal myocardial infarction from all studies reporting these as outcomes.](images/primary.png)

# Secondary composite endpoint

![Forest plot for the incidence of the secondary composite endpoint of CV death, nonfatal MI and TVR.](images/secondary.png)

# Change in angina burden

![Forest plot for change in Seattle Angina Questionnaire summary score following CTO-PCI. SMD, standardized mean difference.](images/saq.png)